Condition

Tricuspid Regurgitation

ClinicalTrials.gov condition label

Clinical trials19
Recruiting6
Common interventions20
Lead sponsors shown15

Clinical trials

19 shown
Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.NCT07464106 · 2025-02-01
RECRUITING
ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid RegurgitationNCT06838611 · 2023-11-14
RECRUITING
European Registry of Transcatheter Repair for Tricuspid RegurgitationNCT06307262 · 2023-10-23
RECRUITING
Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®NCT05114850 · 2022-04-20
RECRUITING
Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve RepairNCT05179616 · 2020-11-30
RECRUITING
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD PatientsNCT02537769 · 2015-08-01
RECRUITING
Biventricular Remodeling in Transcatheter Tricuspid Valve Replacement - Acute Hemodynamic Instability StudyNCT06954792 · 2027-01-01
ENROLLING_BY_INVITATION
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional EchocardiographyNCT07292896 · 2025-12-01
NOT_YET_RECRUITING
Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)NCT06667128 · 2025-02-01
NOT_YET_RECRUITING
Application of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume OverloadNCT06663566 · 2024-08-15
ENROLLING_BY_INVITATION
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)NCT06137807 · 2024-07-23
ACTIVE_NOT_RECRUITING
Enavogliflozin Outcome Trial in Functional Tricuspid RegurgitationNCT06027307 · 2023-10-25
ACTIVE_NOT_RECRUITING
Early Discharge After Mitral and Tricuspid Edge-to-edge Repair: an Assessment of Feasibility and SafetyNCT06343363 · 2023-05-01
COMPLETED
Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Severe Tricuspid RegurgitationNCT05497141 · 2022-07-22
UNKNOWN
The Long-term Course of Moderate Tricuspid RegurgitationNCT06169345 · 2021-05-01
COMPLETED
Hemodynamic Implications of Transcatheter Tricuspid Valve Repair in HFpEF PatientsNCT04782908 · 2021-03-01
UNKNOWN
Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure EntitiesNCT04570098 · 2020-07-26
COMPLETED
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves ReplacementNCT02644616 · 2014-11-01
COMPLETED
Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000NCT00665301 · 2008-03-01
COMPLETED

Common interventions

Diagnose the patient's right heart function as well as right heart fibrosisDIAGNOSTIC_TEST1Diagnose the patients right heart function as well as right heart fibrosisOTHER1Early discharge protocolBEHAVIORAL1Echocardiographic evaluationOTHER1Elecsys® NT-proBNP - Roche DiagnosticsDIAGNOSTIC_TEST1EnavogliflozinDRUG1Left ventricular assist device (LVAD)DEVICE1Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair SystemDEVICE1PlaceboDRUG1placebo+torasemideDRUG1Rapid Up-Titration GDMT Group with Hospital MonitoringOTHER1Rapid Uptitration of Guideline-Directed Medical TherapyOTHER1T-TEERDEVICE1tolvaptan+torasemideDRUG1Transcatheter edge-to-edge repairDEVICE1Transcatheter edge-to-edge repair (TEER)PROCEDURE1Transcatheter edge-to-edge tricuspid valve repairPROCEDURE1Transcatheter tricuspid valve edge-to-edge repairDEVICE1Tricuspid Valve Repair (TVR)PROCEDURE1TricValve® Transcatheter Bicaval Valve SystemDEVICE1

Trial status mix

RECRUITING6
COMPLETED5
ACTIVE_NOT_RECRUITING2
ENROLLING_BY_INVITATION2
NOT_YET_RECRUITING2
UNKNOWN2

Phase mix

NA5
PHASE31
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.